Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrowhead Tumbles As FDA Puts A Clinical Hold On Novel HBV Therapy Trial

Executive Summary

Shares in US biotech Arrowhead Pharmaceuticals took a tumble after the FDA put a clinical hold on one of its small interfering RNAs (siRNAs) Phase II programs in hepatitis B because of concerns over a delivery vehicle that is also used in two of its other Phase II candidates.

Advertisement

Related Content

Hep B Cure May Lie In Reducing Surface Antigen
Stockwatch: Bluebird, Arrowhead And Short Memories
Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal
Arrowhead gets $35m bargain for Novartis RNAi assets with Alnylam targets
Arrowhead plummets on FDA partial hold

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel